ONCS Key Statistics, Chart & Performance
The current stock price of ONCS is 0.2772 USD. In the past month the price decreased by -44.42%. In the past year, price decreased by -98.4%.
ONCS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.29 | 388.96B | ||
| AMGN | AMGEN INC | 14.91 | 175.60B | ||
| GILD | GILEAD SCIENCES INC | 14.79 | 150.25B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.72 | 117.69B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.7 | 83.72B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 780.96 | 52.62B | ||
| INSM | INSMED INC | N/A | 37.53B | ||
| NTRA | NATERA INC | N/A | 32.34B | ||
| BIIB | BIOGEN INC | 11.21 | 27.52B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 22.94B | ||
| INCY | INCYTE CORP | 16.65 | 20.98B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.31 | 20.81B |
Related stock screener links
About ONCS
Company Profile
OncoSec Medical, Inc. is a biotechnology company focused on designing, developing and commercializing therapies and proprietary medical approaches to stimulate and to guide an anti-tumor immune response for the treatment of cancer. The company is headquartered in Ewing, New Jersey and currently employs 40 full-time employees. The company went IPO on 2015-05-29. The firm is focused on designing, developing and commercializing intra-tumoral DNA-based therapeutics delivered by electroporation (EP) to stimulate and augment anti-tumor immune responses for the treatment of cancers. Its technology platform, ImmunoPulse, is a drug-device therapeutic modality comprised of intertumoral EP delivery devices, such as the OncoSec Medical System (OMS) EP device. The OMS EP device is designed to deliver plasmid DNA-encoded drugs directly into a solid tumor and promote an immunological response against cancer. The OMS EP device adapts to treat different tumor types and consists of an electrical pulse generator, a reusable handle and disposable applicators. Its product candidate, TAVO is a drug-device combination. The drug consists of a plasmid construct called tavokinogene telseplasmid (TAVO) with plasmid DNA-encoded, IL-12, and is delivered into a tumor using its electroporation device.
Company Info
OncoSec Medical Incorporated
820 Bear Tavern Road
Ewing NEW JERSEY 08534 US
CEO: Margaret Dalesandro
Employees: 40
Phone: 18582107333.0
OncoSec Medical Incorporated / ONCS FAQ
What does OncoSec Medical Incorporated do?
OncoSec Medical, Inc. is a biotechnology company focused on designing, developing and commercializing therapies and proprietary medical approaches to stimulate and to guide an anti-tumor immune response for the treatment of cancer. The company is headquartered in Ewing, New Jersey and currently employs 40 full-time employees. The company went IPO on 2015-05-29. The firm is focused on designing, developing and commercializing intra-tumoral DNA-based therapeutics delivered by electroporation (EP) to stimulate and augment anti-tumor immune responses for the treatment of cancers. Its technology platform, ImmunoPulse, is a drug-device therapeutic modality comprised of intertumoral EP delivery devices, such as the OncoSec Medical System (OMS) EP device. The OMS EP device is designed to deliver plasmid DNA-encoded drugs directly into a solid tumor and promote an immunological response against cancer. The OMS EP device adapts to treat different tumor types and consists of an electrical pulse generator, a reusable handle and disposable applicators. Its product candidate, TAVO is a drug-device combination. The drug consists of a plasmid construct called tavokinogene telseplasmid (TAVO) with plasmid DNA-encoded, IL-12, and is delivered into a tumor using its electroporation device.
What is the current price of ONCS stock?
The current stock price of ONCS is 0.2772 USD. The price increased by 31.87% in the last trading session.
Does ONCS stock pay dividends?
ONCS does not pay a dividend.
What is the ChartMill technical and fundamental rating of ONCS stock?
ONCS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
ONCS Technical Analysis
ONCS Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ONCS. Both the profitability and financial health of ONCS have multiple concerns.
ONCS Financial Highlights
Over the last trailing twelve months ONCS reported a non-GAAP Earnings per Share(EPS) of -19.14. The EPS increased by 39.16% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | N/A | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ONCS Forecast & Estimates
6 analysts have analysed ONCS and the average price target is 5.1 USD. This implies a price increase of 1739.83% is expected in the next year compared to the current price of 0.2772.